Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Pasithea Therapeutics Corporation KTTA

Alternate Symbol(s):  KTTAW

Healthcare Biotechnology
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:KTTA)

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

GlobeNewswire 12 days ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

GlobeNewswire November 28, 2025

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

GlobeNewswire November 25, 2025

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

GlobeNewswire November 24, 2025

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

GlobeNewswire November 21, 2025

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

GlobeNewswire November 20, 2025

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire November 4, 2025

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire September 16, 2025

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire September 8, 2025
View More News ››

Opinion & Analysis (NDAQ:KTTA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KTTA)

Sell buddy sell.

Otherwise you guys out there will be losing your money with this stock today anyway
coolfooldumbguy - 13 days ago

KTTA....sure would be nice to have participated in the P.O

and have Mr. M "taking care of business" for u I'd say the whole P.O has been shorted to all the Chasers for the past 3...
Iseneschal - November 28, 2025

KTTA ....sold to America !!!!!

Thanks for the excellent profit !!!!!
Iseneschal - November 28, 2025

KTTA....and of course it is stronger

WTF do I know....Halted right away  The norm is for these Shitco's to go down Ok I'm long now Show me the money Mr. M !!...
Iseneschal - November 28, 2025

KTTA ....I told ya....Here u go ...a P.O !!!

  Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock   2025-11-28 06:20 ET...
Iseneschal - November 28, 2025

KTTA....This what I think about today's NR

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for...
Iseneschal - November 26, 2025
View more Bullboard ››

AJA Health and Wellness Inc

AJA Health and Wellness Inc

AJA Health and Wellness Inc. operates a telemedicine platform and full-service travel clinics. The company offers virtual ...
View More »